Department of Neurosurgery, Nagasaki Kawatana Medical Center, Nishi-kyusyu Brain and Nerve Center, Higashi Sonogi-gun, Kawatana-machi, Shimokumigo 2005-1, Nagasaki 859-3615, Japan.
J Clin Neurosci. 2013 May;20(5):740-1. doi: 10.1016/j.jocn.2012.04.024. Epub 2013 Mar 5.
Neuroleptic malignant syndrome (NMS), also called parkinsonism-hyperpyrexia syndrome (PHS), is a severe, general, sometimes fatal, physical reaction, induced by sudden and strong blockade of dopamine receptors. When subthalamic nucleus (STN)-deep brain stimulation (DBS) is used on patients with Parkinson disease (PD), dopaminergic medications are transiently stopped prior to the procedure, and a reduction in the use of drugs is routinely attempted after the procedure. Although a sudden stop or abrupt reduction of dopaminergic medications may set the stage for NMS/PHS, only three cases have been reported after STN-DBS surgery. Here, we describe a 75-year-old woman with PD who experienced delayed onset, yet fatal, PHS after STN-DBS. Although STN-DBS might prevent or suppress PHS, its protective effect is not always complete. We must be aware that fatal PHS can occur when the use of medication for PD is reduced or altered, even when patients are under continuous STN stimulation.
神经阻滞剂恶性综合征(NMS),又称帕金森高热综合征(PHS),是一种严重的、全身性的、有时致命的躯体反应,由多巴胺受体的突然和强烈阻滞引起。当对帕金森病(PD)患者进行丘脑底核(STN)深部脑刺激(DBS)时,在手术前会暂时停止使用多巴胺能药物,并且在手术后通常会尝试减少药物的使用。虽然突然停止或突然减少多巴胺能药物可能会为 NMS/PHS 奠定基础,但仅在 STN-DBS 手术后报告了三例。在这里,我们描述了一例 75 岁女性 PD 患者,在 STN-DBS 后发生迟发性但致命的 PHS。尽管 STN-DBS 可能预防或抑制 PHS,但它的保护作用并不总是完全的。我们必须意识到,即使患者持续接受 STN 刺激,当 PD 药物的使用减少或改变时,也可能发生致命的 PHS。